Y-Intercept (HK)’s Standard BioTools LAB Stock Holding History

Y-Intercept (HK)’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-263,273	Closed	-$217K	–	1862
2026 Q2	$217K	Buy	+263,273	New	+$249K	﹤0.01%	1554
2024 Q2	–	Sell	-110,882	Closed	-$300K	–	1662
2024 Q1	$300K	Buy	110,882 +71,374	+181%	+$172K	0.02%	952
2023 Q4	$87.3K	Buy	+39,508	New	+$84.3K	0.01%	1113
2023 Q2	–	Sell	-31,647	Closed	-$61.7K	–	1520
2023 Q1	$61.7K	Buy	+31,647	New	+$62.5K	0.01%	1098
2022 Q3	–	Sell	-13,132	Closed	-$21K	–	1133
2022 Q2	$21K	Buy	+13,132	New	+$32.5K	﹤0.01%	787

Other funds holding LAB

DIM

DLK Investment Management Solana Beach, California $275M AUM 10.69% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Y-Intercept (HK)'s LAB Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Standard BioTools (LAB) in Q3 2026, closing a stake of 263,273 shares — an estimated $217K sold.

Y-Intercept (HK) first reported a position in LAB in Q2 2022 and held it in 5 quarters. The position peaked at $300K in Q1 2024. 3 funds tracked by Wall St. Rank hold LAB as of Q3 2026.

Y-Intercept (HK) reported no remaining Standard BioTools position as of Q3 2026 after selling out during the quarter.
Y-Intercept (HK) sold 263,273 Standard BioTools shares in Q3 2026, an estimated $217K.
Y-Intercept (HK) first reported a position in Standard BioTools in Q2 2022 and held it in 5 quarters.
Y-Intercept (HK)'s Standard BioTools position peaked at $300K in Q1 2024.
3 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.